Evidence map›Paper›PMID 37264472›Full record

ArticleAddiction science & clinical practice2023

Prevalence and predictors of suicidality among adults initiating office-based buprenorphine.

Michelle R Lent, Karen L Dugosh, Emily Hurstak, Hannah R Callahan, Kimberly Mazur, Greater Philadelphia Opioid Use Disorder Research Group

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Addiction science & clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04257214 naactive not recruitingnot on this map

Identifying Optimal Psychosocial Interventions for Patients Receiving Office-Based Buprenorphine

TypeinterventionalSponsorPhiladelphia College of Osteopathic MedicineRan2020 to 2026Enrolled340ConditionsOpioid Use DisorderArmsPsychosocial treatment
NCT04650386 nacompletednot on this map

Enhancing Office-based Buprenorphine Treatment: An Adaptive Psychosocial Approach

TypeinterventionalSponsorPublic Health Management CorporationRan2020 to 2024Enrolled125ConditionsOpioid-use DisorderArmsPsychosocial support determined by adaptive treatment algorithm
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Michelle R LentSchool of Professional and Applied Psychology, Philadelphia College of Osteopathic Medicine, 4190 City Avenue, Rowland Hall, Philadelphia, PA, 19131, USA. michellele@pcom.edu.ORCID 0000-0001-7892-1879
Karen L DugoshResearch and Evaluation Group, Public Health Management Corporation, 1500 Market Street, Philadelphia, PA, 19102, USA.
Emily HurstakBoston University School of Medicine, 801 Massachusetts Avenue, 2nd floor, Boston, MA, 02118, USA.
Hannah R CallahanSchool of Professional and Applied Psychology, Philadelphia College of Osteopathic Medicine, 4190 City Avenue, Rowland Hall, Philadelphia, PA, 19131, USA.
Kimberly MazurAtlantiCare HealthPlex, 1401 Atlantic Avenue, Atlantic City, NJ, 08401, USA.
Greater Philadelphia Opioid Use Disorder Research Group
AtlantiCare · USPhiladelphia College of Osteopathic Medicine · USBoston University · USPublic Health Management Corporation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIndividuals who have substance use disorders may have an elevated risk of suicidality. This study sought to examine the prevalence of, and identify factors associated with, suicidality in adults with opioid use disorder (OUD) initiating office-based buprenorphine treatment.

methodsIndividuals were eligible to participate if they had OUD and had initiated treatment in the past month. Participants (n = 244) completed a semi-structured interview using the Addiction Severity Index-Lite.

resultsAt baseline, 37.70% of participants reported significant thoughts of suicide over their lifetime and 27.46% reported suicidal attempts over their lifetime. Logistic regression analyses were used to identify predictors of lifetime suicidal thoughts and attempts. A history of physical abuse (OR = 4.31, p < .001), having chronic pain-related conditions (OR = 3.28, p < .001), a history of depression (OR = 3.30, p = .001) or anxiety (OR = 7.47, p = .001), and Latino/a/x ethnicity (OR = 2.66, p = .01) were associated with an increased risk of lifetime suicidal thoughts. A history of sexual abuse (OR = 2.89, p = .01), Latino/a/x ethnicity (OR = 4.01, p < .001), a history of depression (OR = 4.03, p = .001) or anxiety (OR = 15.65, p = .007) and having a chronic pain-related condition (OR = 2.43, p = .01), were associated with an increased risk of lifetime suicide attempts.

conclusionsResults demonstrate the high prevalence of suicidal thoughts and attempts among patients initiating buprenorphine. Findings may help to better identify at-risk patients and to inform screening, prevention, and mental health treatment efforts.

trial registrationClinicalTrials.gov, NCT04650386 (registered 12 December 2020, https://clinicaltrials.gov/ct2/show/NCT04650386 ) and NCT04257214 (registered 5 February 2020, https://clinicaltrials.gov/ct2/show/NCT04257214 ).

Indexed as

BuprenorphineChronic PainSuicideAdultHumansPrevalenceRisk FactorsSuicidal IdeationBuprenorphineOpioid use disorderRisk factorsSuicide

Identifiers

PMID37264472
PMCPMC10233176
OpenAlexW4378983596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.